TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23189924

Group type: EXPERIMENTAL
Intervention: Negotiated treatment plan
Number of subjects: 324

Group type: COMPARATOR
Intervention: No negotiated treatment plan
Number of subjects: 324

Group type: COMPARATOR
Intervention: Negotiated treatment plan at fewer than three time points
Number of subjects: 324
Study: 21241290

Group type: EXPERIMENTAL
Intervention: MgCl(2) 2.5 g daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (inactive solution)
Number of subjects: 106
Study: 18055171

Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation with intravenous heparin
Number of subjects: 115

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 115
Study: 16585320

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 30-45 seconds
Number of subjects: 72

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) at 5-10 seconds
Number of subjects: 72
Study: 12837899

Group type: EXPERIMENTAL
Intervention: Use of North American Guidelines for Children's Agricultural Tasks (NAGCAT)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: High parental knowledge of child development
Number of subjects: 450
Study: 9706914

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (control)
Number of subjects: 31
Study: 8576291

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fluid therapy
Number of subjects: 86
Study: 2774145

Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve blocks (Group 1, 12 patients)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interpleural catheter with local anaesthetic immediately after surgery (Group 2, 12 patients)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interpleural catheter with local anaesthetic at three hours (Group 3, 12 patients)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Provision of catheter 'top‐ups' between six and 18 hours after surgery
Number of subjects: 36
Study: 708810

Group type: EXPERIMENTAL
Intervention: 120dB tones
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 120dB fast rise-time tones
Number of subjects: 64
Study: 30530342

Group type: EXPERIMENTAL
Intervention: Pinning controller design algorithm for PBN stabilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinning nodes selected for control inputs
Number of subjects: 0
Study: 26951796

Group type: EXPERIMENTAL
Intervention: Difficult patients' vignettes
Number of subjects: 74
Study: 24677033

Group type: EXPERIMENTAL
Intervention: HQK-1001 (2,2-dimethylbutyrate) at 15 mg/kg twice daily for 48 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: HQK-1001
Number of subjects: 76
Study: 22952648

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% fat)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: High-fat diet (40-45% fat)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Replication study (8-week diet of 880 kcal/d and 20% fat)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Waist reduction
Number of subjects: 771
Study: 19442592

Group type: EXPERIMENTAL
Intervention: Home-based cycle exercise program with non-invasive ventilation (NIV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Home-based cycle exercise program without non-invasive ventilation (NIV)
Number of subjects: 16
Study: 17299114

Group type: EXPERIMENTAL
Intervention: Large portion condition
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reference condition
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self-selection condition
Number of subjects: 75
Study: 15339465

Group type: EXPERIMENTAL
Intervention: Xiangdan Injection plus standard treatment for coronary heart disease
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment for coronary heart disease (Control)
Number of subjects: 56
Study: 11996874

Group type: EXPERIMENTAL
Intervention: Integrated stress management program (7 sessions of 1 hour over 4 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Integrated stress management program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (tape only)
Number of subjects: 47
Study: 9817278

Group type: EXPERIMENTAL
Intervention: Two cycles of MCV chemotherapy before concurrent cisplatin and radiation therapy (arm 1, n=61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard induction therapy (arm 2, n=62)
Number of subjects: 123
Study: 7654489

Group type: EXPERIMENTAL
Intervention: Intravenous dexfenfluramine (d-F) 15.5 mg base infused over 3 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral dexfenfluramine (d-F) 25.9 mg base in capsules
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous and oral dexfenfluramine (d-F)
Number of subjects: 20
Study: 2668525

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiloride + Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study: 671150

Group type: EXPERIMENTAL
Intervention: Proprietary infant formula (supplemented with iron)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cow milk formula (no iron supplementation)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Breast feeding (no iron supplementation)
Number of subjects: 132
Study: 30864006

Group type: EXPERIMENTAL
Intervention: PPB + IRLA (3.0 mL of 2% lidocaine injected at the bilateral pelvic plexus)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: PNB + IRLA (3.0 mL of 2% lidocaine injected at both periprostatic nerves)
Number of subjects: 163

Group type: COMPARATOR
Intervention: IRLA alone
Number of subjects: 163
Study: 28072681

Group type: EXPERIMENTAL
Intervention: Group-focused cognitive behavioral health education program (GCBHEP) for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional counseling for 10 weeks
Number of subjects: 20
Study: 25847131

Group type: EXPERIMENTAL
Intervention: Alteplase 0.1 mg/kg twice a day on days 1 and 3 or days 2 and 4
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 27
Study: 23667063

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 54
Study: 21224458

Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 757

Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 757
Study: 19473751

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18034178

Group type: EXPERIMENTAL
Intervention: March of Dimes NICU Family Support (NFS)
Number of subjects: 0
Study: 16176939

Group type: EXPERIMENTAL
Intervention: DMPA-SC 104 (104 mg/0.65 ml every 3 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: DMPA-SC 104
Number of subjects: 300

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: DMPA-SC 104 and Leuprolide
Number of subjects: 300
Study: 14639444

Group type: EXPERIMENTAL
Intervention: DJATA1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DJATA2
Number of subjects: 6
Study: 10581822

Group type: EXPERIMENTAL
Intervention: Homoeopathic care
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard GP care
Number of subjects: 33
Study: 9170576

Group type: COMPARATOR
Intervention: Hormonal therapy (goserelin acetate depot 3.6 mg subcutaneously every 4 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (goserelin acetate depot 3.6 mg subcutaneously and cyclophosphamide 1000 mg/m2 intravenously every 4 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy
Number of subjects: 41
Study: 1951075

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (40 mg every 6 hours for 6 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low-dose sotalol
Number of subjects: 300
Study: 7230984

Group type: EXPERIMENTAL
Intervention: Oral antimicrobial bowel preparation with metronidazole and kanamycin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Parenteral antibiotic prophylaxis with metronidazole and kanamycin
Number of subjects: 72
Study: 31919035

Group type: EXPERIMENTAL
Intervention: Small sided games (SSG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Large sided games (LSG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mini-goal games (MG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Friendly matches (FM)
Number of subjects: 14
Study: 30047802

Group type: EXPERIMENTAL
Intervention: 12-week programme plus 6 physical activity counselling sessions
Number of subjects: 36

Group type: COMPARATOR
Intervention: 12-week programme comprising an orientation and access to fitness centre resources
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physical activity counselling
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Increases from baseline in IPAQ moderate/vigorous activity minutes
Number of subjects: 36
Study: 29306228

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TnX‐A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (Des)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: TnX‐A + Des
Number of subjects: 54
Study: 25875795

Group type: EXPERIMENTAL
Intervention: Single-step treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: 2-step treatment
Number of subjects: 47
Study: 23571173

Group type: EXPERIMENTAL
Intervention: Two-dose inactivated hepatitis A vaccine (Healive(®))
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: One-dose inactivated hepatitis A vaccine (Healive(®))
Number of subjects: 5

Group type: COMPARATOR
Intervention: Attenuated vaccine B
Number of subjects: 5

Group type: COMPARATOR
Intervention: Attenuated vaccine C
Number of subjects: 5

Group type: COMPARATOR
Intervention: Attenuated vaccine A
Number of subjects: 5
Study: 21819749

Group type: EXPERIMENTAL
Intervention: 8 mg of i.v. dexamethasone preoperatively and again after 24 and 48 hours after surgery
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Three pseudoephedrine tablets (60 mg) per day for 1 week
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Three pseudoephedrine tablets (60 mg) per day for 2 weeks
Number of subjects: 74
Study: 20068365

Group type: EXPERIMENTAL
Intervention: alpha-interferon 0.5 million IU b.i.d., thalidomide (100 mg b.i.d. reduced to 100 mg daily), or celecoxib (400 mg daily reduced to 200 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: two-drug combinations of alpha-interferon, thalidomide or celecoxib
Number of subjects: 62

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 62
Study: 17565807

Group type: EXPERIMENTAL
Intervention: Ampicillin and gentamicin for 7 days, starting between 24 and 36 hours of life
Number of subjects: 144

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ampicillin and gentamicin
Number of subjects: 144
Study: 15507074

Group type: EXPERIMENTAL
Intervention: Frailty index based on comprehensive geriatric assessment (FI-CGA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 169
Study: 11281338

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg and verapamil 180 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg and amlodipine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trandolapril 2 mg
Number of subjects: 0
Study: 9400948

Group type: EXPERIMENTAL
Intervention: CPT‐11 (irinotecan) and VP‐16 (etoposide) given sequentially in Arm A: CPT‐11 over 90 min on days 1-3, VP‐16 over 60 min on days 4-6
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: VP‐16 (etoposide) and CPT‐11 (irinotecan) given sequentially in Arm B: VP‐16 on days 1-3, CPT‐11 on days 4-6
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: G-CSF given daily on days 7-17 to all patients
Number of subjects: 27
Study: 7955195

Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) grafts
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: IMA plus vein grafts
Number of subjects: 912

Group type: COMPARATOR
Intervention: Vein grafts
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Clinical events in group 1 (IMA and vein grafts)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Clinical events in group 2 (only vein grafts)
Number of subjects: 912
Study: 3622189

Group type: EXPERIMENTAL
Intervention: Pattern-recognition program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human scorers
Number of subjects: 0
Study: 31427901

Group type: EXPERIMENTAL
Intervention: HG-Herbst
Number of subjects: 26

Group type: COMPARATOR
Intervention: HG-TB
Number of subjects: 26
Study: 28544917

Group type: EXPERIMENTAL
Intervention: Mannitol 0.5g/kg and Furosemide 0.5mg/kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mannitol 1g/kg and Furosemide 0.5mg/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mannitol 0.5g/kg and Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mannitol (0.5g/kg or 1g/kg) with Furosemide (0.5mg/kg)
Number of subjects: 51
Study: 24931756

Group type: EXPERIMENTAL
Intervention: Parenteral Dipeptiven(®) supplementation of 0.5 g/kg/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard isocaloric isoproteinic nutritional support
Number of subjects: 82
Study: 23609487

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy‐based self‐help program delivered by the Internet with e‐mail guidance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bibliotherapy with e‐mail guidance
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (Internet and bibliotherapy)
Number of subjects: 29
Study: 21902998

Group type: EXPERIMENTAL
Intervention: Pulpectomy with smear layer removal (Group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pulpectomy without smear layer removal (Group 2)
Number of subjects: 18
Study: 19176222

Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT) combined with treatment-as-usual (TAU)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 32
Study: 17076982

Group type: EXPERIMENTAL
Intervention: IM aripiprazole 9.75 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: IM haloperidol 6.5 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Oral haloperidol
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: IM aripiprazole
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: IM haloperidol
Number of subjects: 325
Study: 15474895

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg p.o. QD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12126875

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg administered orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 9576366

Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol (5.4 ± 1.2 microg/week, maximum 6.6 ± 1.5 microg/week) administered twice per week before bedtime.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol
Number of subjects: 8
Study: 7539187

Group type: EXPERIMENTAL
Intervention: UroLume Endourethral Prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: thermosensitive and biodegradable prostheses
Number of subjects: 0
Study: 2651014

Group type: EXPERIMENTAL
Intervention: 4.5 mg ergoloid mesylates per day
Number of subjects: 97
Study: 144507

Group type: EXPERIMENTAL
Intervention: 100 mg D-penicillamine (DP)
Number of subjects: 179

Group type: COMPARATOR
Intervention: 5 mg D-penicillamine (DP)
Number of subjects: 179
Study: 31422458

Group type: EXPERIMENTAL
Intervention: IV PCA oxycodone
Number of subjects: 270

Group type: COMPARATOR
Intervention: Oral oxycodone
Number of subjects: 270
Study: 26882121

Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 and NR1I2 T/T mutations
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wild-type subjects
Number of subjects: 42
Study: 25432952

Group type: EXPERIMENTAL
Intervention: 125 µg peginterferon beta‐1a every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125 µg peginterferon beta‐1a every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (initially assigned)
Number of subjects: 0
Study: 23245590

Group type: EXPERIMENTAL
Intervention: Tretinoin (45mg/m²/day) for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Peg-interferon and ribavirin alone
Number of subjects: 57
Study: 21288774

Group type: EXPERIMENTAL
Intervention: Protease inhibitor and switch to second-line at 1000 copies per mL (PI-low)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Protease inhibitor and switch at 30,000 copies per mL (PI-higher)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: NNRTI and switch at 1000 copies per mL (NNRTI-low)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: NNRTI and switch at 30,000 copies per mL (NNRTI-higher)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Switching at low threshold (1000 copies per mL)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Switching at higher threshold (30,000 copies per mL)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: NNRTI-higher group
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: All treatment strategies
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Protease inhibitor resistance
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: CDC stage-C events and grade 3/4 adverse events
Number of subjects: 266
Study: 19480232

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Number of subjects: 27
Study: 16081106

Group type: EXPERIMENTAL
Intervention: CBZ plus FEWP
Number of subjects: 235

Group type: COMPARATOR
Intervention: CBZ monotherapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 15143081

Group type: EXPERIMENTAL
Intervention: G-CSF + EPO
Number of subjects: 38

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 38
Study: 10831021

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg, administered orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8922889

Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin during surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1348773

Group type: EXPERIMENTAL
Intervention: Y-set dialysate delivery system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard dialysate delivery system
Number of subjects: 40
Study: 3910160

Group type: EXPERIMENTAL
Intervention: Stump invagination
Number of subjects: 735

Group type: COMPARATOR
Intervention: Simple ligation
Number of subjects: 735
Study: 31862436

Group type: EXPERIMENTAL
Intervention: 12-month personalized, remotely delivered survivorship care plan (SCP) intervention
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: $50 upfront incentive
Number of subjects: 342

Group type: COMPARATOR
Intervention: $25 upfront incentive
Number of subjects: 342

Group type: COMPARATOR
Intervention: Different recruitment strategies (shorter approach packets and tiered consent)
Number of subjects: 342
Study: 31752872

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) for family planning education and support
Number of subjects: 0
Study: 28330629

Group type: EXPERIMENTAL
Intervention: Needle
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cannula over needle
Number of subjects: 500
Study: 26100026

Group type: EXPERIMENTAL
Intervention: HEADS‐UP intervention (structured, multidisciplinary team briefing)
Number of subjects: 7840

Group type: EXPERIMENTAL
Intervention: HEADS‐UP intervention
Number of subjects: 7840
Study: 23941053

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) programme
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (standard university courses)
Number of subjects: 288
Study: 21957940

Group type: EXPERIMENTAL
Intervention: Encircling constriction of the superficial femoral vein with colour Doppler monitoring
Number of subjects: 87

Group type: COMPARATOR
Intervention: Encircling constriction of the superficial femoral vein without colour Doppler monitoring
Number of subjects: 87
Study: 19828031

Group type: EXPERIMENTAL
Intervention: CPI>0
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: At least one tooth lost
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Tooth loss in molars
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Tooth loss in molar-and anterior regions
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (bad breath)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (chewing problem)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (toothache)
Number of subjects: 877
Study: 16721192

Group type: EXPERIMENTAL
Intervention: Homeopathic remedy No‐Shift‐Lag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15587753

Group type: EXPERIMENTAL
Intervention: Cefcapene pivoxil (CFPN-PI; 450 mg/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Cefteram pivoxil (CFTM-PI; 600 mg/day)
Number of subjects: 171
Study: 10828762

Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease (PKD)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis (CGN)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Other nephropathies
Number of subjects: 886
Study: 9293055

Group type: EXPERIMENTAL
Intervention: FP 100 micrograms b.d. via Accuhaler/Diskus inhaler (n = 159)
Number of subjects: 323

Group type: COMPARATOR
Intervention: BUD 200 micrograms b.d. via Turbohaler inhaler (n = 164)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Accuhaler/Diskus inhaler
Number of subjects: 323

Group type: COMPARATOR
Intervention: Turbohaler inhaler
Number of subjects: 323
Study: 8227491

Group type: EXPERIMENTAL
Intervention: CGI severity ratings
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CGI improvement ratings
Number of subjects: 116